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Background: Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are 
two inflammatory conditions affecting people aged over 50 years. PMR is 
characterized by pain and stiffness in the shoulder and hip girdles. GCA, a large 
vessel vasculitis, is the most common form of primary systemic vasculitis. About 
40-60% of patients with GCA present with concomitant PMR, and histologic 
features consistent with GCA can be detected on temporal artery biopsy of about 
16% to 21% of patients with PMR. It is still debated whether PMR and GCA are 
different conditions or represent different clinical manifestations across the 
spectrum of a single disease. The aim of this research project was to profile 
immunological and imaging aspects of these two conditions to better 
characterize their similarities and differences. 
Patients and methods: A cohort of unselected, consecutive patients with PMR, 
GCA or both was studied. PMR was diagnosed according to Bird et al. criteria, 
whereas patients with cranial (C)-GCA were diagnosed according to the 1990 
ACR classification criteria; a subset of these patients underwent temporal artery 
biopsy. Five further patients with fever of unknown origin (FUO) and imaging 
evidence of large vessel vasculitis (LVV) were included. All patients underwent 
a detailed and standardized clinical examination and, subsequently, a 18F-
Fluorodeoxyglucose (FDG) positron emission tomography (PET) scan.. Joint 
and vascular uptake were evaluated by a qualitative visual score, using the liver 
uptake as a reference, and with semi-quantitative mean standardized uptake 
value (SUV). Each value of the qualitative joint and vascular scores of every 
region were summed up to obtain a total joint score (TJS) and a total vascular 
score (TVS). In a subgroup of patients, serum samples were collected just before 
the injection of FDG on the same day of the PET scan. The soluble (s) immune 
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checkpoints cytotoxic T-lymphocyte antigen-4 (CTLA-4), soluble programmed 
death-1 (sPD-1) and programmed death-ligand 1 and 2 (PD-L1 and PD-L2) were 
measured in this subgroup. The serum of fifty healthy controls were studied for 
comparison. 
Results: One hundred and thirty-one patients underwent FDG-PET/CT 
scanning, including 89 females and 42 males, with a median age of 74 years 
(range 47-92). Ninety-seven patients were diagnosed as PMR, 13 as C-GCA, 16 
with both PMR and C-GCA and five patients presented with FUO.  
Soluble CTLA-4, sPD1, sPD-L1, and sPD-L2, evaluated in 40 patients (32 with 
PMR and 8 with PMR+C-GCA), were increased in comparison with controls 
(p<0.001 for all the comparisons), although no statistically significant difference 
between patients with PMR+C-GCA and those with isolated PMR was found. 
Conclusions: Patients with PMR and GCA share many immunological and 
imaging abnormalities. Results from this study demonstrate that available and 




1. INTRODUCTION and BACKGROUND 
Polymyalgia rheumatica (PMR) is an inflammatory disease of the elderly, 
characterized by aching and stiffness in the scapular and pelvic girdles1,2. Giant 
cell arteritis (GCA) is the most frequent systemic vasculitis in the adult over fifty 
years of age, involving large and medium size vessels. The hallmark of these 
two diseases is a strong inflammatory response and both occur in people of the 
same age range as well as ethnical and geographic groups.  
About 40-60% of patients with GCA present concomitant PMR, and histologic 
features consistent with GCA can be detected on temporal artery biopsy in about 
16% to 21% of patients with PMR3. As a consequence, some authors have 
hypothesized that PMR and GCA could be different expressions of the same 
disease4.  
Large vessel vasculitis (LVV) is a generic term used to define the presence of 
inflammation in the aorta and its major branches. According to the 2012 Revised 
International Chapel Hill Consensus Conference Nomenclature of Vasculitides5, 
LVV “is vasculitis that affects large arteries more often than do other 
vasculitides”. The two main diseases in this category are GCA and Takayasu 
arteritis, which are considered very similar in terms of histology and are 
classically differentiated by age of onset, although recent studies have 
underlined more similarities between these two diseases than previously 
thought6. LVV however is an umbrella term, under which other diseases are also 
included. In this group, one emerging entity is the so-called “idiopathic aortitis”, 
also referred to as “isolated aortitis”, defined as the presence of pathologic 
inflammation in aortic segments (detected by imaging techniques or surgical 
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pathology), without clear clinical evidence of a systemic rheumatologic disease 
to account for the vasculitis7. 
Imaging studies, especially with 18F-fluorodeoxyglucose (FDG) positron 
emission tomography (PET), have shown the presence of LVV in up to 30-40% 
of patients with apparently isolated PMR8 and in 70-80% of patients with GCA9, 
although these figures are strongly influenced by the techniques used to interpret 
imaging results9–11. The detection of an otherwise occult LVV is a crucial issue, 
because LVV could be related to the development of aneurysms12,13 and 
ischaemic complications. Nevertheless, clinical or laboratory features, 
predictive of the presence of LVV in patients with PMR or GCA, are not yet 
available8,14.  
LVV is increasingly clinically recognized, mostly because of the evolution and 
wider utilization of advanced imaging techniques. However, defining the clinical 
prevalence of LVV is difficult, because many clinical characteristics of 
vasculitis, such as fever, weight loss and malaise are nonspecific and difficult to 
attribute to a rheumatologic disease, especially in non-specialized settings15. In 
routine clinical practice, and in specialty tertiary centres, patients with isolated 
LVV are generally classified as having either GCA or Takayasu arteritis16, but 
there is a real possibility that these patients constitute a different nosologic 
group. In fact, patients with isolated aortitis seem to be younger than patients 
with GCA16,17 and more susceptible to aortic damage requiring surgery17. 
The purpose of the investigations forming the basis of this thesis is to examine 
the relationship between PMR, GCA and LVV, in order to understand if they are 




2. ROLE OF POSITRON EMISSION TOMOGRAPHY (PET) 
2.1. PET and polymyalgia rheumatica 
The first paper on the use of PET in PMR patients was published by Blockmans 
et al, in 199918. In four out of five patients with PMR without clinical signs of 
GCA, they found increased FDG uptake in at least one vascular district, among 
arteries of thorax, upper and lower limbs. The only patient with PMR without 
vascular uptake had a lower C-reactive protein (CRP) than those with uptake. 
Among the 6 patients with biopsy proven GCA, only 1 did not show vascular 
uptake. The control group comprised 23 patients with various diseases, including 
leukaemia, rheumatoid arthritis, monoclonal gammopathy or unspecified 
diagnosis. In the control group, 8/23 patients had increased vascular uptake, 
which in two of them was thought possibly related to atherosclerosis. The most 
inflammation-specific site was the thoracic aorta, with only 1/23 controls 
showing uptake in that district. Interestingly, the only patient with biopsy-proven 
GCA but no FDG-uptake suffered from diffuse atherosclerosis, although the 
diagnostic criteria used to ascertain it were not clear. The four PMR patients 
underwent a second PET scan after glucocorticoid treatment, when symptoms 
disappeared and inflammatory parameters returned to normal, showing a clearly 
decreased vascular uptake18.  
The same authors subsequently increased the number of observations studying 
25 patients with GCA or PMR, of whom 13 had biopsy proven temporal arteritis 
and 12 had negative biopsy19. PMR was diagnosed according to Healey and 
Hunder criteria. Vascular FDG uptake was described in 10 of these patients with 
GCA (76.9%), in nine patients with PMR (75%) and in 10 out of 44 controls 
(22.7%) who suffered from other diseases such as infections, rheumatoid 
arthritis or small vessel vasculitis. Among the patients with PMR or GCA who 
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did not show FDG vascular uptake, four out of six had marked uptake in the 
shoulders. Uptake in the large joints was seen in 12 of 25 (48%) patients with 
PMR or GCA, as well as in 14 of 44 (31.8%) controls, some of whom had 
diagnosed arthritis. Thoracic vascular FDG uptake had a sensitivity of 56% for 
the diagnosis of GCA or PMR, a specificity of 98% and a positive predictive 
value of 93%. A negative scan had a negative predictive value of 80%. Vascular 
FDG uptake in the legs had a slightly greater sensitivity of 64% but a lower 
specificity of 77%. 
Moosig et al.20 used FDG-PET evaluated 13 patients with a diagnosis of PMR 
according to the Chuang et al criteria. A group of six patients with inflammatory 
diseases other than PMR served as controls. Three of the patients with PMR had 
presented with concomitant GCA, one had a negative biopsy and the remaining 
9 had no clinical symptoms nor duplex-ultrasound alterations suggestive of 
temporal arteritis. The PET scans were evaluated visually and also by placing a 
region of interest (ROI) on 9 vascular regions, including the ascending thoracic 
aorta, descending thoracic aorta, abdominal aorta, right and left subclavian 
arteries, right and left external carotid arteries, and the right and left common 
iliac arteries. An index was calculated by dividing the value of every ROI with 
that of a peripheral region of the lung. All 12 patients showed increased tracer 
uptake of the aorta or its major branches compared with the controls. However, 
the control subjects were few and significantly younger than the patients with 
PMR, a fact that could have biased the results.  
The mean ROI index for all nine regions was 1.58±0.37 in the PMR group and 
0.93±0.12 in controls (p=0.001). Among the various vascular areas evaluated, 
the locations best discriminating between active PMR and controls were the 
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subclavian and external carotid arteries. Eight patients underwent a second PET 
scan after three months of high dose glucocorticoid treatment, while they were 
in partial or complete remission. In this group, the uptake decreased from a ROI 
index of 1.50±0.16 to 1.09±0.08 (p=0.001). However, the uptake in the 
subclavian arteries remained higher in patients in remission than in controls. In 
patients with PMR, there was a strong correlation between CRP, erythrocyte 
sedimentation rate (ESR) and platelet count with the intensity of vascular uptake. 
In a more recent study by Blockmans et al.21, which included some of the patients 
reported in the previous studies, FDG-PET was performed in 35 patients with 
isolated PMR, diagnosed according to Healey and Chuang criteria and after 
excluding GCA by temporal biopsy, obtained in 30 of 35 patients. To increase 
specificity, patients with visual disturbance, headache or jaw claudication were 
excluded.  
Two different nuclear medicine specialists scored the FDG uptake in seven 
vascular regions (thoracic aorta, abdominal aorta, subclavian arteries, axillary 
arteries, carotid arteries, iliac arteries and femoral arteries) as negative (0) or 
positive, and further scored the uptake semi-quantitatively as 1 (minimal but not 
negligible FDG uptake), 2 (clearly increased FDG uptake) or 3 (very marked 
FDG uptake). Then they calculated a ‘total vascular score’ (TVS) ranging from 
0 (no vascular FDG uptake in any of the seven vascular regions) to 21 (vascular 
FDG uptake scored 3 in all seven territories). Both subclavian, axillary, carotid, 
iliac and femoral arteries were counted as one vascular region; when the score 
differed from right to left artery, the highest score was taken for that vascular 
region. FDG uptake in the shoulder and hip regions and in the spinous processes 
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of the vertebrae was scored as 0 (no uptake), 1 (moderate uptake) or 2 (intense 
uptake). 
At the first PET scan, 11/35 (31.4%) patients had vascular uptake with mean 
TVS of 0.8±1.7. Increased uptake was noted in the subclavian arteries in 10 
patients, in the thoracic aorta in four, in the axillary arteries, the abdominal aorta 
and the iliac arteries in two each, and in the femoral and carotid arteries in one 
each. Thirty-three out of 35 (93.4%) patients had FDG uptake in the shoulders 
with a mean score of 1.7±0.6. 
FDG uptake was seen in the spinous processes (mean score 0.6±0.7) of the 
lumbar vertebrae in 15 patients, at the dorsal level in seven patients (of whom 
five had also an increased FDG uptake in the spinous processes of the lumbar 
spine) and in the cervical spine in three patients (of whom two also had uptake 
at the lumbar level). At follow up, vascular and joint uptake persisted, although 
diminished, in most patients, especially at six months. Interestingly, the intensity 
of uptake did not predict the occurrence of PMR relapses, although the power of 
the study was limited by the fact that only a few patients completed it22.  
Similar findings, although with different frequency and severity, were also 
observed in a study on patients with GCA23. Indeed, twenty-nine of 35 (82.9%) 
patients with GCA had FDG uptake at least in one district, with a mean TVS of 
6.0 ± 6.2. Eleven of 35 (31.4%) patients showed FDG uptake in the shoulders 
with a score ≥2, and 17 (48.6%) with a score of 1.  
In a short report, three out of eight patients with glucocorticoid-resistant PMR 
investigated with FDG-PET were found to be affected by LVV14. This 
percentage, which is not different from that found in untreated PMR patients, 
suggests that the low-dose glucocorticoid therapy, which is usually given to 
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patients with PMR, might be not sufficient for the treatment of concomitant 
LVV. Yamashita et al.24 evaluated 14 patients with PMR with FDG-PET/CT and 
17 patients with other rheumatic diseases (mainly rheumatoid arthritis). They 
found that the intensity of FDG uptake in ischial tuberosities, greater trochanters 
and spinous processes was higher in patients with PMR, whereas wrists and hips 
showed higher uptake in controls. Shoulders, elbows and sternoclavicular joint 
did not differ significantly between the two groups. 
 
2.2. PET and giant cell arteritis 
GCA is also known as Horton’s or temporal arteritis, for its peculiar involvement 
of the superficial temporal arteries. Although autopsy studies demonstrated the 
presence of large vessel involvement in patients with PMR and GCA25,26, the 
first descriptions of large vessel uptake detected by FDG-PET in patients with 
fever of unknown origin (FUO) appeared in the late 1990’s18,27. The exact 
prevalence of large vessel involvement in GCA is controversial, and depends on 
the selection of the patients, disease duration, ongoing treatment, and the 
technique used to evaluate large vessels. Regarding FDG-PET/CT, one critical 
issue is the definition of vasculitis, since an accepted definition of pathological 
large vessel uptake is still lacking28,29. Several scores have been proposed for the 
evaluation of large vessel uptake, both qualitative and semi-quantitative, but a 
definitive consensus has not yet been reached9.  
In 2003, Meller et al. evaluated 15 patients with FDG-PET and introduced one 
of the first and most widely used methods for grading large vessel uptake, based 
on a visual score30. They found increased uptake in 59 of the 104 (56%) arterial 
districts studied. Fourteen of these patients also underwent (magnetic resonance 
imaging (MRI); pathologic alterations were detected in 13 of these patients in at 
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least one arterial site. Fourty-seven vascular regions out of the 76 (61.8%) 
evaluated with both PET and MRI were concordantly positive or negative with 
both techniques. 
Using a visual score ≥2 as positive, the presence of large vessel involvement was 
reported in 15 out of 26 (58%) patients with GCA or TAK by Walter et al.31, in 
29 out of 35 (83%) patients with GCA by Blockmans et al.23, and in 20 out of 
25 (80%) patients with GCA by Both et al.32. In the latter study, all patients 
additionally underwent thoracic MRI32; clinical and serological parameters 
showed a weak correlation with FDG-PET findings, whereas no significant 
correlation was found with MRI32.  
In a retrospective study33, 62 out of 304 (20%) of PET scans performed on the 
basis of clinical suspicion of LVV were positive for large vessel uptake. In 
comparison with patients with a negative scan, those with a positive PET were 
more frequently female, older, received a previous diagnosis of temporal 
arteritis, suffered less frequently from arthralgia and presented with higher levels 
of thrombocytes and ESR. 
Prieto-González et al.34, in a well-designed study, showed that maximum 
standardised uptake values (SUV) of all arteries studied in 71 GCA patients were 
higher than those of 20 controls without systemic inflammatory diseases, and 
that SUV correlated with inflammatory markers. 
Stellingwerff et al.11 retrospectively reviewed 18 patients with GCA and 
evaluated their PET scans. They used two qualitative visual scoring methods and 
four semi-quantitative methods and reported that the best performance of the 
score for presence of vasculitis was when vascular uptake was higher than liver 
uptake using the aorta-to-liver ratio with a cut-off of 1.03. In both cases, 
 13 
diagnostic accuracy increased when patients taking glucocorticoids were 
excluded. 
It is well known in clinical practice that some patients whose onset is typical of 
PMR relapse with symptoms of GCA35, underscoring the strong relationship 
between these two disease entities.  
There is increasing evidence of the existence of two different patterns of GCA. 
Cranial disease is characterized by typical symptoms such as headache, jaw 
claudication and visual disturbances. The other pattern is dominated by large 
vessel involvement, in which signs of vascular insufficiency, aneurysms/stenosis 
and polymyalgia rheumatica are prevalent36–38. In clinical practice, these 
presentations may be mixed with different nuances. The 1990 American College 
of Rheumatology criteria, although intended for classification and not for 
diagnostic purposes, completely neglected the presence of LVV39. The 
Diagnostic and Classification Criteria in Vasculitis Study (DCVAS) will soon 
provide new classification criteria for LVV, taking into account how the 
tremendous technological progress in imaging techniques has changed our 
understanding of LVV40. 
 
2.3. PET and large vessel vasculitis 
In the 2012 Chapel Hill Consensus Conference nomenclature scheme, LVV was 
defined as vasculitis that involves large arteries more often than other 
vasculitides, and include GCA and TAK as the two main entities of LVV5. 
However, the involvement of large vessels, especially the aorta, by inflammatory 
processes is seen in a wide variety of conditions, including rheumatoid arthritis, 
ankylosing spondylitis, systemic lupus erythematosus, relapsing polychondritis, 
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Cogan syndrome, Behçet’s disease and immunoglobulin G4-related disease 
(IgG4-RD)7.  
IgG4-RD can present with lymphoplasmacytic aortitis and can exclusively 
involve the adventitia, as a periaortitis. This condition can affect the aorta and 
other large and medium size vessels. FDG-PET can show the protean 
manifestations of IgG4-RD, which range from vascular to lymphatic and other 
glands involvement. Indeed, virtually every organ can constitute a target41–43. 
One major issue of published literature on FDG-PET in LVV is the mixture of 
patients with GCA and TAK in the same cohort. While there is some evidence 
to suggest that these two conditions could be different manifestations of the same 
disease44, other authors highlight significant differences that justify classifying 
them as separate disease entities45. 
The major problem in applying imaging techniques currently in use for 
evaluation of LVV is the absence of a pathologic confirmation of the underlying 
disease. In fact, every study addressing sensitivity and specificity of MRI or 
FDG-PET is based on clinical diagnosis, or in some cases on histology of 
temporal arteries. A systematic histologic description of vessels which show 
uptake with FDG-PET is lacking, hampering our confidence in published results, 
especially in patients with a mild grade vasculitis. Few cases with pathologic 
description of FDG large vessel uptake have been published. In one of them, 
labelled as GCA, a markedly thickened aortic wall and extensive multifocal 
perivascular chronic inflammation, composed mainly of lymphocytes and 
plasma cells was seen at surgical pathology, findings that could also be 
consistent with IgG4-RD7. 
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In 2018, the European League against Rheumatism (EULAR) published 
evidence-based recommendations for the use of imaging in LVV46. An early 
imaging test is suggested in patients with suspected GCA to confirm the 
diagnosis. Ultrasound is the first-choice imaging technique to detect cranial 
arteries involvement, whereas PET and MRI are best suitable for the assessment 
of aortic and large-vessel involvement. 
 
2.4. PET and fever of unknown origin 
The key to identifying the correct diagnosis in patients with fever of unknown 
origin (FUO) is the clinical history and examination, that, if carefully and 
repeatedly conducted, can successfully lead to the correct diagnosis in up to one-
third of patients when combined with laboratory testing47. FDG-PET can 
identify the most frequent causes of FUO (i.e. neoplasms, infections, 
inflammatory diseases). Nevertheless, in up to 10-40% of patients with FUO a 
final diagnosis is lacking48,49. An emerging entity is the “inflammation of 
unknown origin” (IUO), defined as an increase of CRP or of ESR, in patients 
presenting with nonspecific signs and symptoms including fatigue, malaise, 
weight loss, anorexia and night sweats in whom a diagnosis is not reached after 
conventional diagnostic procedures50. These features are in many cases the 
presentation of patients with vasculitis. Whereas substantial literature has been 
published on FUO, few papers have analysed the characteristics of patients with 
IUO, although one paper found striking similarities with FUO50, suggesting 
adoption of the same diagnostic workup for both conditions. 
FDG-PET/CT has been proposed as a fundamental step, although not in the early 
stage, of diagnostic work-up of patients with inflammation and fever of unknown 
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origin. Although expensive, it could ultimately be cost-effective, sparing time 
and other diagnostic resources51. 
In a cohort of 240 patients with FUO and IUO52, fifteen percent of those with 
FUO received a final diagnosis of adult-onset Still’s disease, whereas LVV and 
PMR accounted for the final diagnosis in 21% and 18.3% of cases with IUO, 
respectively. In 136 (57%) patients of the total cohort, FDG-PET/CT was 





Figure 1. PET/CT: transaxial view at the shoulder girdle level in a patient 
diagnosed as polymyalgia rheumatica. Note the intense uptake of gleno-humeral 
and sterno-clavicular joints and of the origin of the left subclavian artery. 
 
Figure 2. PET, coronal reconstruction. Same patient as figure 1. Note the intense 




3. IMMUNE CHECKPOINTS 
The immune system is fine-tuned to achieve a balance between excessive 
activation, which may lead to self-damage due to uncontrolled inflammation, 
and excessive inhibition, which may lead to an unopposed proliferation of 
pathogens and tumour cells. Immune checkpoints are a group of receptors that 
inhibit the activation of immune cells. They comprise the anti-cytotoxic T 
lymphocyte antigen-4 (CTLA-4) and the programmed cell death protein-1 (PD-
1)53,54.  
CTLA-4 is a member of the immunoglobulin superfamily that is expressed on 
the surface of lymphocytes and acts as an immune checkpoint. It is involved in 
the costimulatory pathways of T cells, competing with CD28 in the binding with 
CD80/86 and thus exerting inhibitory effects on the immune system55. CTLA-4 
has been shown to play a role both in neoplastic56,57 and autoimmune diseases58. 
A soluble form of the CTLA-4 molecule, resulting from alternative splicing, has 
been identified. Soluble CTLA-4 retains the ability to bind its physiological 
ligands and may exert an immunomodulatory function via competitive binding. 
Serum soluble CTLA-4 levels have been reported to be markedly increased in 
several autoimmune diseases58. 
PD-1 is expressed on the surface of T cells, B cells and monocytes59. T cells 
activation causes an up-regulation of PD-1, which is crucial for the termination 
of the immune response. PD-L1 and PD-L2, the ligands of PD-1, are expressed 
on antigen presenting cells and other non-hematopoietic cells, including vascular 
endothelial cells59. Soluble forms of PD-1 and PD-L1 have been described as 
well60,61. The binding of the sPD-1 to the membrane-bound form may have an 
immunostimulatory effect, preventing the connection with PD-L1 and therefore 
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blocking the transduction of the inhibitory message62. An up-regulation of the 
PD-1/PD-L1 pathway is present in rheumatoid arthritis63. Knock-out mice for 
the PD-1 gene showed an increased susceptibility to the induction of collagen-
induced arthritis, but this was reversed with a treatment with PD-L1Fc63.  
James P. Allison demonstrated in 1996 that anti-CTLA-4 antibodies enhanced 
the immune response against tumour in mice64. Tasuku Honjo isolated the PD-1 
gene, demonstrating its role in the programmed cell death65, and showed that the 
ligand of PD-1 (PD-L1), a member of the B7 gene family, can inhibit T 
lymphocyte proliferation via the binding with PD-166. In 2018, the Nobel prize 
in Medicine was awarded to Allison and Honjo for their pivotal discovery of 
cancer therapy based on the inhibition of the negative regulator of the immune 
system.  
Ipilimumab is a fully human monoclonal antibody against CTLA-4 which 
“enhances” T lymphocytes activation through the increased binding of CD 80/86 
with CD28. It is licensed for the treatment of metastatic melanoma and 
metastatic renal cell carcinoma56. A number of drug-related or drug-induced 
immune adverse events have been reported, as a consequence of the growing use 
of immune checkpoint inhibitors, targeting CTLA-4 and PD-167. Involvement of 
CTLA-4 and its soluble form has been demonstrated in several autoimmune 
diseases58,68. 
The rationale for studying the role of immune checkpoints in PMR and GCA is 
provided by the anecdotal evidence of drug-induced PMR/GCA in patients 
treated with ipilimumab69,70 and other checkpoint inhibitors71,72. Moreover, there 
is evidence that temporal artery specimens from patients with active GCA show 
low levels of PD-L1 transcripts and high levels of PD-1 transcripts73. On the 
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contrary, arteries from healthy donors showed high levels of PD-L1 transcripts 
but almost complete absence of PD-1 transcripts, indicating lack of T cells in the 
wall of normal vessel. The use of an anti-PD-1 antibody in a mouse model of 
GCA increased vascular inflammation and T cell infiltration73. These findings 
suggest a deficiency of the immune checkpoint activity in GCA74, a hypothesis 





4. THE STUDY 
4.1. Objectives 
The objectives of the present study were: 
1. to evaluate via FDG-PET/CT patients with PMR, GCA, the association 
of both of them, and FUO; to compare their pattern of uptake; and to 
correlate their clinical characteristics with imaging findings 
2. to analyse the soluble checkpoint inhibitors in patients with PMR and 
GCA and to test whether these biomarkers can be used to identify 
patients with GCA and/or LVV 
3. to provide insight as to whether these conditions can be considered as 
different entities or as a continuum within the same disease or syndrome. 
 
4.2. Patients and methods 
4.2.1. Inclusion criteria 
All patients were recruited from January 2009 to April 2016. Patients with PMR 
were diagnosed on the basis of Bird et al. criteria76, patients with cranial (C)-
GCA according to the 1990 American College of Rheumatology criteria77, and 
patients with FUO according to Durack and Street criteria48. More details are 
provided in the appendix. 
 
4.2.2. Clinical and laboratory assessment 
All patients underwent a careful clinical history and subsequent standardized 
physical examination. Disease duration, morning stiffness, presence of fever, 
weight loss, headache, jaw claudication, visual disturbance, spontaneous pain in 
the girdles and in the spine and previous glucocorticoid therapy were recorded. 
Clinical examination included pain on application of digital pressure at the long 
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head of the biceps (LHB), the sub-acromial area (SA), the ischiatic (IB) and 
trochanteric (TB) bursae, the sacro-iliac joints, and on mobilization of the 
shoulder and hip girdles, recorded in a dichotomous manner as “presence” or 
“absence” of pain. Also assessed were degree of arm elevation, presence of 
peripheral arthritis, abnormalities of temporal arteries and presence of vessel 
murmurs and of limb claudication. All sites of spontaneous or provoked pain 
(“total sites of pain”, TSP) were summed. CRP, ESR and blood cell count were 
obtained for all patients. In patients with FUO, a diagnostic work-up was carried 
out to exclude the main causes of fever, including obtaining of blood cultures, 
screening for neoplastic diseases, etc. on the basis of the underlying clinical 
picture. 
 
4.2.3. PET/CT acquisition 
FDG-PET/CT was performed in all patients. After a minimum of 6 hour fasting, 
a dose of 4.8-5.2 MBq of F18-FDG per kilogram body weight was injected 
through a peripheral vein catheter. Patients were placed in a quiet room and 
instructed remain still. Data acquisition started ≥60 minutes after intravenous 
administration of 18F-FDG. Patients underwent simultaneous FDG-PET and 
computed tomography (CT) imaging from the skull base to the thighs using an 
integrated PET/CT scanner (Hirez; Siemens Medical Solutions, Knoxville TN, 
USA). In some patients, the scan included also legs and feet, if they seemed 
clinically involved. PET raw data were reconstructed by means of ordered subset 
expectation maximization and attenuation correction was performed using the 
CT raw data. The entire CT dataset was fused with the 3-dimensional PET 
images using an integrated software interface (Syngo Image Fusion; Siemens 
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Erlangen, Germany) to create anatomical images superimposed with FDG 
uptake.  
 
4.2.4. Image analysis 
Joint and vascular uptake was scored both semi-quantitatively with a visual score 
and quantitatively. Regions of interest (ROIs) were placed on the anatomic CT 
images to identify four aortic segments (ascending, arch, descending and 
abdominal), subclavian arteries, common carotid arteries, iliac and femoral 
arteries; ROIs were drawn on the theoretical vessel wall (figure 3) to exclude the 
uptake of the blood inside the vessel lumen. A further region was drawn within 
the left ventricular chamber using the PET image to estimate the tracer 
concentration in the arterial blood (blood-pool, BP). To assess joint metabolism 
CT-based ROIs were bilaterally drawn on the gleno-humeral, sterno-clavicular, 
and coxo-femoral joints, and on the trochanteric and ischiatic bursae (figure 4). 
Arterial FDG uptake was quantified by calculating the mean standardized uptake 
value (SUV) within each ROI. To take into account the contribution of FDG 
activity in the blood, results were expressed as the ratio between mean SUV 
value of each ROI and blood-pool ROI (SUV/BP), expressing true arterial wall 
metabolic activity; joint FDG uptake was considered without BP ratio. 
To evaluate the presence and extent of atherosclerosis, total arterial calcium load 
(ACL) was also estimated in the same arterial segments. For this purpose, 
calcium density was graded according to a semi-quantitative 5 point scale based 
on percentage of calcification of the arterial ring documented in the trans-axial 
CT views: 0=no calcific deposits; 1=0-25%; 2=25-50%; 3=50-75% and 4=75-
100%, with a possible score ranging between 0 and 48. 
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Figure 4. PET/CT, transaxial view. Articular ROIs drawn on both gleno-humeral 
joint spaces. 
 
Arterial and joint uptake was visually graded using a four-point scale, as 
proposed by Walter et al.31: 0=no uptake present, 1=uptake present but lower 
than liver uptake, 2=similar to liver uptake, 3=uptake higher than liver uptake. 
To determine the prevalence of each finding, these scores were further 
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subdivided as “negative” (0 and 1) and “positive” (2 and 3) (figure 5). For each 
patient, the sum of the four-point score of vascular and joint uptake was recorded 
as total visual vascular score (TVS), with a maximum score of 36, and total 
visual joint score (TJS), also taking into account uptake in cervical and lumbar 
interspinous bursae, with a maximum score of 36.  
 
Figure 5. PET, coronal reconstruction. Grade 3 uptake of the right and left 
carotid arteries, of the ascending aorta and of the aortic arch (uptake is higher 
than that of the liver). Right subclavian artery shows a grade 2 uptake (left 
subclavian artery is not displayed in this slice). 
 
4.2.5. Laboratory analysis 
In a subgroup of 40 patients, serum samples were collected the same day of the 
PET scan, before the infusion of FDG. Serum sCTLA-4, sPD-1, sPD-L1 and 
sPD-L2 were measured by ELISA (EMELCA Bioscience, 
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www.emelcabio.com) according to the manufacturer’s instructions. Each 
sample was diluted 1:10 and tested in duplicate. Deviation between duplicates 
was <10% for any reported value and the detection limit of the assay was 0.1 
ng/ml. The analytical response was linear between 0.162 and 1.200 of 
absorbance values (corresponding to 0.1 - 50 ng/ml) as assessed by serial 
dilution test using a strongly positive serum sample. Intra-assay Precision 
(Precision within an assay) was <8%, whereas Inter-assay Precision (Precision 
between assays) was <6%. 
Serum sPD-1 was measured by ELISA (EMELCA Bioscience, 
www.emelcabio.com) according to the manufacturer’s instructions. Each 
sample was diluted 1:10 and tested in duplicate. Deviation between duplicates 
was <10% for any reported value and the detection limit of the assay was 0.156 
ng/ml. The analytical response was linear between 0.162 and 3.000 of 
absorbance values (corresponding to 0.156 - 10 ng/ml) as assessed by serial 
dilution test using a strongly positive serum sample. Intra-assay Precision 
(Precision within an assay) was <10%, whereas Inter-assay Precision (Precision 
between assays) was 12%. 
Serum sPD-L1 was measured by ELISA (EMELCA Bioscience, 
www.emelcabio.com) according to the manufacturer’s instructions. Each 
sample was diluted 1:10 and tested in duplicate. Deviation between duplicates 
was <10% for any reported value and the detection limit of the assay was 0.156 
ng/ml. The analytical response was linear between 0.162 and 2.800 of 
absorbance values (corresponding to 0.156 - 10 ng/ml) as assessed by serial 
dilution test using a strongly positive serum sample. Intra-assay Precision 
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(Precision within an assay) was <10%, whereas Inter-assay Precision (Precision 
between assays) was 12%. 
Serum sPD-L2 was measured by ELISA (EMELCA Bioscience, 
www.emelcabio.com) according to the manufacturer’s instructions. Each 
sample was diluted 1:10 and tested in duplicate. Deviation between duplicates 
was <10% for any reported value and the detection limit of the assay was 0.062 
ng/ml. The analytical response was linear between 0.162 and 2.600 of 
absorbance values (corresponding to 0.062 - 10 ng/ml) as assessed by serial 
dilution test using a strongly positive serum sample. Intra-assay Precision 
(Precision within an assay) was <10%, whereas Inter-assay Precision (Precision 
between assays) was 12%. 
Serum interleukin 6 (IL-6) was measured by ELISA (ImmunoTools GmbH, 
Friesoythe, Germany), according to the manufacturer's instructions. Each 
sample was diluted 1:10 and tested in duplicate. The deviation between 
duplicates was <10% for any reported value, and the detection limit of the assay 
was 6.1 pg/ml. The analytical response was linear between 0.162 and 1.400 of 
absorbance values (corresponding to 6.1 - 500 pg/ml) as assessed by serial 
dilution test using a strongly positive serum sample.  
White blood cells (WBC), platelets (PLT), haemoglobin (Hb), CRP and ESR 
values were retrieved from patients’ routine laboratory examinations, performed 
in the week preceding the FDG-PET/CT scan. 
A group of 40 age- and sex-matched healthy controls, without any known 
inflammatory and neoplastic disease, was also included in this study. 
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4.2.6. Statistical analysis 
Analysis was performed using IBM SPSS Statistics software. The comparison 
of means was evaluated with Student’s t-test and ANOVA with Bonferroni 
correction. Medians were compared with the Mann-Whitney or Kruskall-Wallis 
tests. The correlations between variables were evaluated with the Pearsons’ test 
if normally distributed and with the Spearman’s rho test if non-parametrical. 
Statistical significance was assumed as p<0.05. 
  
4.3. Results 
4.3.1. Patient characteristics 
One hundred and thirty-one patients were included, 89 women and 42 men, with 
a median age of 74 years (range 47-92). Ninety-seven patients were diagnosed 
as PMR, 13 as C-GCA, 16 with both PMR and C-GCA and 5 patients presented 
with FUO (figure 6). Demographic, clinical and laboratory data are shown in 
table 1. Sixteen patients underwent temporal artery biopsy, of these, 10 were 
positive. Five out of thirteen (38.4%) patients with GCA and four out of sixteen 
(31.2%) patients with both PMR and GCA had a positive temporal artery biopsy. 
Forty-three out of 131 (32.8%) patients were already taking glucocorticoids at 










Variable (unit of measure) Value (range) 
Men (n) 42 
Women (n) 89 
Median age (years) 74 (range 47-92) 
Median disease duration (days) 85 (range 4-1957) 
Median Hgb (g/L) 126 (range 82-168) 
Median WBC (x109/L) 8.4 (range 4.3-15) 
Median PLT (x109/L) 321 (range 108-643) 
Median ESR (mm/h) 59 (range 8-140) 
Median CRP (mg/L) 34.7 (range 0.4-162) 











4.3.2. Evaluation of vascular uptake 
4.3.2.1. Comparison of vascular uptake between patient groups 
Mean SUV of arterial districts are shown in figure 7. Patients with PMR showed 
a statistically significant lower mean arterial SUV in comparison to patients with 
FUO (0.77 vs. 1.15, p=0.004); patients with C-GCA showed a tendency towards 
lower uptake in comparison to patients with FUO (0.81 vs 1.14, p=0.052). 
 
 
Figure 7. Columns represent the means of vascular SUV, with standard deviation 
of each group. 
  
Similar results were obtained using visual scoring, although differences between 
groups seemed more striking. Mean TVS values are shown in figure 8. Patients 
with a clinical diagnosis of FUO showed increased uptake in large vessel in all 
cases. PMR patients showed statistically lower TVS than patients with PMR+C-















Figure 8. Columns represent the means of total vascular score (TVS) with 
standard deviation of each group. 
 
Reference group Comparison group p 
PMR vs. PMR+C-GCA 0.022 
 C-GCA <0.001 
 FUO <0.001 
PMR+C-GCA vs. C-GCA n.s. 
 FUO 0.009 
C-GCA vs. FUO n.s. 
Table 2. Multiple comparison of mean TVS between patient groups (n.s.: not 
significant). 
 












PMR PMR+C-GCA C-GCA FUO
Mean TVS
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As expected, vascular SUV and TVS showed correlation (p<0.001), with a 
coefficient of 0.299. 
 
4.3.2.3. Comparison of vascular uptake between patients with and without 
glucocorticoid therapy 
There were no significant differences in vascular uptake between the 88 
glucocorticoid-naïve patients at the time of PET/CT and the 43 who were already 
taking glucocorticoids, considering both mean arterial SUV (0.78 vs 0.82, 
respectively) and visual score (mean TVS of 14.15 vs 14.7). 
 
4.3.2.4. Arterial calcium load 
Patients with GCA showed a tendency to higher mean ACL in comparison with 
the other patient groups (figure 9), although the difference was not statistically 
significant (p=0.058). ACL did not differ between patients who were taking GC 




Figure 9. Columns represent the means of total arterial calcium load (ACL) with 
standard deviation of each group. 
 
4.3.2.5. Correlation between vascular uptake and temporal artery biopsy  
Mean vascular SUV was not significantly higher in patients in whom the 
temporal artery biopsy was positive compared to those with negative biopsy, 
although those with a positive showed a tendency toward higher values. In 
contrast, patients with a positive biopsy showed a statistically significant higher 
TVS compared to those with a negative biopsy (p=0.015) or those not 
undergoing biopsy (p=0.003). 
 
4.3.2.6. Correlation between vascular uptake and clinical and laboratory 
variables 
Mean arterial SUV did not correlate significantly with the presence of fever 














PMR PMR+C-GCA C-GCA FUO
Mean ACL
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alterations (n=8), and palpable (n=15), pulseless (n=9), or tender temporal artery 
(n=16). Mean arterial SUV correlated inversely with haemoglobin concentration 
(p=0.05), and positively with PLT, CRP, ESR (p=0.026, p=<0.001, p=0.002, 
respectively); no correlation was noted with WBC. 
Conversely, patients who presented with fever showed a higher mean TVS than 
those without (p=0.007). The same was true for patients with headache (p=0.04), 
patients with visual alterations (p=0.036), and patients with a thickened temporal 
artery (p=0.027). Pain at pressure of the temporal artery showed no significant 
correlation with mean TVS, as well as weight loss and jaw claudication. Mean 
Hgb concentration was inversely correlated with mean TVS (p=0.002), whereas 
PLT, CRP and ESR showed a positive correlation with mean TVS (p=0.005, 
p=0.001, p=004 respectively); WBC did not correlate with TVS. 
 
4.3.2.7. Dichotomic evaluation of vascular uptake 
Using a visual uptake of ³2 in at least one large vessel to define a positive scan,  
forty-nine out of 97 (50.5%) patients with PMR had a positive PET scan, as well 
as 12 out of 16 (75%) of patients with PMR+C-GCA, eleven out of 13 (84.6%) 
patients with C-GCA and 5 out of 5 (100%) with FUO. Using the same standard 
of a visual uptake >2 as a positive scan, fifteen out of 97 (15.4%) patients with 
PMR had a positive scan for vasculitis, seven out of 16 (43.7%) of patients with 
PMR+C-GCA, seven out of 13 (53.8%) patients with C-GCA and 4 out of 5 
(80%) of patients with FUO. 
 
4.3.3. Evaluation of joint uptake 
4.3.3.1. Comparison of joint uptake between patient groups 
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Mean SUV of articular and extra-articular areas considered is shown in figure 
10. Patients with PMR showed a statistically significant higher uptake than C-
GCA patients (p=0.01). 
 
 
Figure 10. Columns represent the mean SUV of articular and extra-articular 
areas with standard deviation of each group. 
 
Mean TJS values are shown in figure 11. Patients with a clinical diagnosis of 
PMR showed the highest mean articular uptake, whereas patients with FUO 
showed the lowest mean articular uptake. Mean TJS of patients with PMR was 













Figure 11. Columns represent the mean TJS of articular and extra-articular areas 
with standard deviation of each group. 
 
4.3.3.2. Comparison of quantitative and visual joint uptake  
Mean joint SUV and mean TJS were positively correlated (p<0.001). 
 
4.3.3.3. Comparison of joint uptake between patients with and without 
glucocorticoid therapy 
Patients who were already taking glucocorticoids at the time of PET/CT showed 
lower uptake than glucocorticoid-naïve patients (p=0.002) when evaluated with 
SUV.  
Also, when evaluated with TJS, patients who were already taking 
glucocorticoids showed lower uptake. 
 









PMR PMR+C-GCA C-GCA FUO
Mean TJS
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Mean SUV of the assessed articular and extra-articular areas correlated 
positively with morning stiffness (MS) (p<0.001) and with total number of 
clinically involved sites. No correlation was found between mean SUV and Hgb 
concentration, PLT, WBC, ESR or CRP. 
Mean TJS correlated positively with MS (p<0.001) and with the total number of 
clinically involved sites (p<0.001). No correlation was found between mean TJS 
and Hb concentration, PLT, WBC, ESR or CRP. 
 
4.3.4. Correlation between vascular and joint uptake 
Because joint involvement is considered more characteristic of PMR but can 
occur in a substantial percentage of patients with GCA, it was of interest to 
assess possible correlation between vascular and joint uptake. TVS and TJS 
correlated negatively (p=0.01), as also did mean vascular SUV and mean joint 
SUV (p=0.001). 
 
4.3.5. Correlation between clinical diagnoses and laboratory/imaging findings 
The ratio between TVS and TJS of patients with PMR was significantly different 
to that of patients with PMR+C-GCA, with C-GCA and with FUO (p<0.01 for 
all comparisons). The ratio between TVS and TJS of patients with PMR+C-GCA 
was significantly different to that of patients with PMR, with C-GCA and with 
FUO. The ratio between TVS and TJS of patients of patients with C-GCA and 
FUO was significantly different to that of patients with PMR and PMR+C-GCA, 
but they did not differ significantly between each other. Patients with a positive 
PET for vasculitis (i.e. a visual score of 3 in at least one vascular region) showed 
a higher value of TVS/TJS in comparison to those without PET-defined 
vasculitis [2 (range 0.6-41) vs 0.5 (range 0-8.5), p>0.01]. Patients with a PET 
positive for vasculitis showed a higher ratio of PLT/WBC (45.8±13.4 vs 





Figure 12. Coronal (on the left) and sagittal (on the right) PET/CT 
reconstructions. Intense uptake of both thoracic and abdominal aorta in a patient 
with FUO. 
 
4.3.6. Soluble immune checkpoints 
Forty consecutive patients with PMR/GCA underwent both FDG-PET/CT and 
serological analysis of soluble immunological checkpoints. Of these, 32 had 
clinically isolated PMR, and 8 patients had PMR with associated C-GCA. The 
blood for these serologic tests was drawn at the time of venepuncture for FDG 
injection. Patient characteristics are given in Table 3.  
The median serum levels of sCTLA-4, sPD-1, sPD-L1 and sPD-L2 in these 
patients were 1.23 ng/ml (range 0.1-122.4), 2.93 ng/ml (range 0.1-7.3), 3.38 
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ng/ml (range 0.1-112.7), and 18.49 ng/ml (range 0.1-411), respectively. In 
control subjects, the median serum levels of sCTLA-4, sPD-1, sPD-L1 and sPD-
L2 were 0.1 ng/ml (range 0.1-1.7), 0,1 ng/ml (range 0.1-0.96), 0,1 ng/ml (range 
0.1-16-1) and 0.3 ng/ml (range 0.1-4.5). Patients had higher concentrations of 
all the analysed soluble immune checkpoints (p<0.001 for all the comparisons). 
Median IL-6 concentration was higher in patients (65.37 pg/ml; range 1-755) 
than in controls (3.4 pg/ml; range 1-6). 
Male patients had a higher median concentration of sCTLA-4 (12.7; range 0.1-
40.7) than female patients (0.1 ng/ml; range 0.1-122.4), p=0.03, whereas levels 
of PD-1, PD-L1, and PD-L2 were comparable. The correlations of sCTLA-4, 
sPD-1, sPD-L1 and PD-L2 with several clinical, laboratory and imaging 
characteristics were explored, including age, morning stiffness, disease duration, 
WBC, PLT, Hgb, CRP, ESR, TVS and TJS, but none of those gave significant 
results. Levels of IL-6 did not correlate with the levels of soluble immune 
checkpoints, nor with the aforementioned clinical and imaging parameters. The 
differences in the concentration of soluble immune checkpoints between patients 
with PMR+C-GCA and those with isolated PMR were not statistically 
significant. This was the also case when comparing patients with and without 
systemic manifestations (i.e. fever and/or loss of weight), those with and without 
potential ischaemic manifestations (i.e. headache, visual disturbances and jaw 
claudication) and those with and without peripheral arthritis and/or 
tenosynovitis. The six patients already taking glucocorticoid treatment had 




Table 3. Characteristics of patients undergoing soluble immune checkpoints 
analysis at the time of the assay. 
Total number 40 
Male, n (%) 8 (20) 
Median age, years 76 (range 50-85) 
Patients with isolated PMR, n (%) 30 (75) 
Patients with PMR+C-GCA, n (%) 10 (25) 
Already taking GC, n (%) 6 (15) 
Systemic manifestations, n (%) 17 (42.5) 
Peripheral arthritis, n (%) 10 (25%) 
Median disease duration, days 87.5 (range 4-1086) 
Median morning stiffness, minutes 60 (range 0-360) 
Mean WBC, 109/L 8.4±1.6 
Mean PLT, 109/L 318.8±92.4 
Mean Hgb, g/L 124±14 
Mean ESR, mm/h 67.7±33.7 




The relationship between PMR and GCA has been always elusive. The high 
prevalence of PMR features among patients with GCA suggests that isolated 
PMR could be a sort of “incomplete form” of GCA, an hypothesis supported by 
imaging19,78 and autopsy studies25. Indeed, the term “polymyalgia arteritica” has 
been suggested because of the presence of vasculitis in apparently isolated forms 
of PMR25. However, some differences seem to exist between isolated (“pure”) 
PMR and PMR associated with GCA79 in terms of age, presence of systemic 
symptoms and laboratory abnormalities. Moreover, patients with PMR who have 
“incidental” findings of a positive temporal artery biopsy, but who do not have 
clinical GCA features, have a lower risk of ischemic complications4, suggesting 
that PMR and GCA could be overlapping, but not necessarily the same disease.  
The widespread use of imaging technique has revealed the presence of LVV in 
a high proportion of patients with PMR80, even though the prognostic 
implications of this finding are still unclear. In this study, the occurrence of LVV 
in patients with apparently “pure” (isolated) PMR was 15.4%, using the strictest 
definition of vasculitis on FDG-PET. On the other hand, PMR is the most 
frequent extra-cranial manifestation of GCA38. There are conflicting results 
about the prognostic implications of concomitant PMR in patients with GCA, 
with some reports suggesting a lower risk of ischaemic events in these patients 
when compared to patients with isolated GCA, even though this finding has not 
been confirmed by others81.  
In the 2012 revised Chapel Hill consensus nomenclature, GCA is defined as an 
arteritis “often granulomatous, usually affecting the aorta and/or its major 
branches, with a predilection for the branches of the carotid and vertebral 
arteries”5. The prototypical clinical picture of temporal arteritis with the 
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presence of headache, temporal artery abnormalities, jaw claudication and visual 
disturbance, is now referred to as “cranial-GCA”38. Patients presenting with 
prevailing involvement of the aorta and its branches, with possible peripheral 
stenosis and limbs claudication, are grouped as “large-vessel-GCA”38. The 
design of this study and the type of referral pattern in our unit facilitated the 
examination of “pure” (isolated) PMR patients, who composed the large 
majority of the present cohort. Although there is a numerical imbalance with the 
other two classes of patients, those with isolated LVV seem to differ in terms of 
PET uptake. 
A pioneering study from Mayo Clinic published in 197582, showed that among 
248 patients with GCA, 34 (14%) had involvement of the aorta or its major 
branches. In 1999, a case-control study showed that patients with angiographic 
signs of vasculitis in the upper limbs rarely presented with cranial 
manifestations. The same also showed a lower frequency of positive temporal 
artery biopsy in patients with vasculitis of the arms, in comparison with a control 
group of "classical" temporal arteritis36. In a Swedish cohort of 164 patients with 
biopsy proven GCA, 24 (15%) had ectasia, aneurysm or stenosis of the aorta or 
its branches83. In a cohort study, patients with C-GCA were compared with 
patients with LV-GCA, defined as those having radiological signs of vasculitis 
in the subclavian arteries37. Patients with LV-GCA were younger than those with 
C-GCA and presented less frequently cranial symptoms (41% vs 83%) and 
vision loss (4% vs 11%). As expected, patients with LV-GCA fulfilled less 
frequently the ACR classification criteria for GCA than those with C-GCA (39% 
vs 95%). Patients with LV-GCA presented a more severe disease course, having 
more relapses and requiring prolonged treatment. Other studies support a lower 
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risk for cranial ischaemic events in patients with LV-GCA compared to those 
with C-GCA81, as well as a more refractory disease course84. . In keeping with 
this study, a currently ongoing follow-up evaluation of a part of the patients 
described in this thesis demonstrated that PMR patients with concomitant LVV 
at PET-CT do not show a worse prognosis than the patients with “pure” 
(isolated) PMR. There is a growing body of evidence for the existence of at least 
two patterns of GCA (i.e. C-GCA vs LV-GCA)38. However, more than half of 
patients with biopsy proven GCA can present with large vessel involvement85, 
suggesting an overlap between these two phenotypes. There is a discrepancy 
between diagnoses based only on clinical and laboratory data and those obtained 
with the aid of imaging. This observation suggests that a new nomenclature is 
necessary to define the spectrum of these conditions. The present results may 
help in this regard. In addition, standardization of PET-CT and other imaging 
techniques is crucial in trying to classify these disorders. 
GCA and Takayasu arteritis represent the two major variants of LVV, according 
to the 2012 revised Chapel Hill consensus nomenclature5. Although they share 
some common clinical44, imaging86 and histopathological7 features, they appear 
to be two different diseases with different manifestations87,88, even when patients 
with Takayasu arteritis are compared with those with extra-cranial 
GCA89.Isolated aortitis is another enigmatic entity: is it a separate condition, 
characterized by exclusive inflammation of the aortic arch, or is it simply another 
presentation of GCA? Although comparison between published papers are 
difficult because of different study designs (imaging vs. surgical vs. autopsy 
studies) and different settings (rheumatology vs. cardiac surgery vs. pathology), 
most of the cases of giant cell aortitis were discovered accidentally, in absence 
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of any specific symptom or sign related to GCA90,91. Among a cohort of 7551 
patients undergoing surgery of the thoracic aorta92, 156 (12%) showed the 
histologic presence of aortitis. Only a minority of them had clinical or 
serological evidence of systemic inflammation, and in 82% of cases, the 
diagnosis was made after the histologic examination, suggesting that a 
significant proportion of patients with aortitis could remain unnoticed. Another 
important drawback of the studies of this topic is that only very few patients did 
have a biopsy of a large artery; as a result, a classical gold standard is lacking. 
It is still unclear whether isolated aortitis represents a sort of aborted, incomplete 
form of GCA93. In a French cohort of patients with radiologically defined 
aortitis17, seventy-three patients with GCA were compared with 44 with isolated 
aortitis. The latter group appeared more at risk of developing aortic aneurysm, 
consistently with other reports94. In the French study, however, when patients 
with isolated aortitis and an age ³60 were compared with those with GCA, many 
characteristics appeared comparable between the two groups.  
The clinical manifestations of GCA can be protean. In some cases, fever can be 
the only presenting symptoms of LVV95; in fact, PMR and GCA account for up 
to one-third of cases of FUO96–98. In a cohort of 100 patients with biopsy proven 
GCA, fifteen presented with FUO as the initial manifestations99. In these 
patients, haemoglobin levels were lower, and platelet count and ESR higher 
compared to the other patients. In a retrospective study of 210 patients with 
biopsy proven GCA100, patients presenting with fever before the starting of GC 
therapy showed lower levels of haemoglobin and higher ESR, but a lower of risk 
of severe ischaemic manifestations. In a cohort of 693 patients with GCA101, 
diagnosed according to biopsy or imaging, sixty-one (9%) initially presented 
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with fever or inflammation of unknown origin as the sole manifestation. These 
patients were younger and presented with higher CRP levels. Nevertheless, no 
differences were seen during follow-up in comparison with patients with 
different initial manifestations. Interestingly, five of the 61 (9%) patients with 
fever or inflammation of unknown origin relapsed with cranial symptoms, not 
present at disease onset. 
In our cohort, FDG-PET revealed evidence of inflammation in large vessels in 
5 patients with FUO. One of them underwent a temporal artery biopsy, which 
was negative. Similar to previous reports, patients presenting with FUO as the 
sole manifestation appeared to have a greater inflammatory response, as shown 
by the higher vascular uptake. All except one of these patients showed a visual 
score of FDG uptake of 3 in the thoracic and abdominal aorta, as well in the 
subclavian, carotid and axillary arteries; the remaining patient, who was already 
taking prednisone, showed a visual score of 2 in the thoracic aorta and the 
subclavian arteries. This distribution of the FDG uptake, extending beyond the 
aorta, makes the diagnosis of isolated aortitis unlikely in these patients.  Given 
the lack of PMR and cranial symptoms, as well the presence of inflammation in 
aortic branches, these patients with FUO may be considered as having isolated 
LVV or LV-GCA.  
Our results suggest that, although on a “disease continuum”, PMR, C-GCA and 
LVV present some distinct features. In particular, we noted a sort of gradient 
from a disease limited to articular and peri-articular areas (“pure” PMR) to a 
vasculitis without any clinical or imaging findings of joint involvement (“pure” 
LVV), as demonstrated by the inverse correlation between both qualitative and 
semi-quantitative scores of joint and vascular uptake. C-GCA (with and without 
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associated PMR) seems to be situated along the road which connects these two 
apparently distant conditions. Although examination of only PET/CT images of 
an individual patient who has of concomitant joint and vascular inflammation 
doesn’t allow the identification of the diagnosis (does the patient have PMR with 
large vessel involvement, or GCA with joint involvement?), it seems that clinical 
diagnosis reflects a “cluster” of inflammation, which could be articular, vascular 
or a combination of the two. 
The findings of this study appear to be only partially affected by glucocorticoid 
treatment. Joint uptake was lower in patients already treated, but vascular uptake, 
although decreased, was not significantly reduced by glucocorticoid use. This 
finding indicates that PET/CT maintains, at least in part, its diagnostic value also 
during established glucocorticoid therapy. In this way, PET/CT is different from 
temporal artery biopsy, the major inflammatory features of which are markedly 
reduced or negative in most patients who have been treated for more than one 
week. More data are needed to understand which doses and duration of 
glucocorticoid treatment are still associated with a positive vascular uptake. In a 
prospective study on patients with LV-GCA, FDG vascular uptake decreased 
after three days of prednisone 60 mg compared to a baseline PET, but the PET 
scans were still positive for vasculitis102. In contrast, after 10 days of treatment, 
only 5 out of 14 patients (35.7%) still showed a positive PET scan. 
In the age group of patients with PMR and GCA, atherosclerosis could be an 
important confounding factor. Atherosclerotic lesions are reported to show both 
increased and reduced FDG uptake, probably depending on the grade of 
inflammation within the plaque103,104. Our patients showed a similar degree of 
ACL, except C-GCA patients who showed higher degree of vascular 
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calcification. The finding that patients on the opposite ends of the spectrum in 
terms of vascular uptake (i.e. patients with PMR and FUO) did not show 
differences in ACL, is reassuring that the study results were not influenced by 
atherosclerosis.  
One major issue in the use of FDG-PET/CT for the evaluation of LVV is the 
absence of standardization about the definition of pathologic vessel uptake. 
Several scores have been proposed to identify the presence and to grade the 
intensity of LVV9,11, but consensus is still lacking.  
One of the most commonly used scores is the visual one chosen for this study. 
This score is readily understandable and easily applied but may be affected by 
inter-reader variability. A quantitative method using SUV could have the 
theoretical advantage of being operator-independent, but it is time consuming. 
Although the results obtained with these two methods were generally concordant 
and showed reciprocal correlation, they yielded slightly different results in this 
study and in a previous one105.  
In the present study, TVS was higher in patients with positive biopsy of the 
temporal artery, a trend that did not reach statistical significance considering 
arterial SUV. Similarly, patients with fever, headache, visual disturbances and 
palpable temporal arteries had higher TVS, a correlation not present with arterial 
SUV, although a tendency towards higher values in this subgroup was present. 
Mean Hb, PLT, CRP and ESR correlated positively with both TVS and arterial 
SUV, suggesting that vascular inflammation is tightly linked with systemic 
inflammation and that marked alterations in these laboratory parameters, in 
absence of an alternative explanation, should rise the suspicion of LVV. 
Conversely, joint inflammation did not appear tightly related to laboratory 
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parameters of inflammation, since neither joint SUV nor TJS correlated with 
Hgb, PLT, CRP or ESR. The total number of clinically involved articular/peri-
articular sites and MS correlated with joint SUV and TJS, confirming that joint 
inflammation is clinically more easily detectable than vascular inflammation. 
The identification of the most reliable and feasible scoring method for the 
detection of abnormal vascular and joint uptake may have practical 
consequences. However, evidence of the need for more active treatment of 
patients with PMR and concomitant LVV is presently lacking. The GiACTA 
trial, the most important trial on the use of the humanised monoclonal anti-
interleukin (IL)-6 receptor antibody tocilizumab in patients with GCA, 
considered as an inclusion criterion the presence of a clinical diagnosis of PMR 
in association with imaging findings of LVV106. This could have been a 
questionable strategy, because, as previously mentioned, it is not actually known 
whether patients who have PMR and concomitant LVV are the same as patients, 
or are actually, patients with GCA4.  
In the current study, an inverse correlation was observed between vascular and 
joint inflammation (expressed both with SUV or visual score). A possible 
explanation for this finding is that different clinical presentations are likely to be 
associated with different referral pathways (e.g. a patient with FUO, without 
joint involvement, may be more likely to be evaluated in an internal medicine 
ward than in a rheumatology outpatient clinic, and the same could happen to a 
patient with only cranial GCA symptoms). Therefore, there may be selection 
bias in the cohort of patients with PMR, and patients with PMR+GCA, who are 
recruited in a rheumatology unit. This is unlikely to have affected the current 
study, as most of the other patients were also evaluated by the same 
 49 
rheumatologists, in some cases as consultants in other wards. Another 
explanation is that the global “inflammatory burden” could be limited and its 
expression could be either restricted only to articular or vascular structures, or 
“equally” divided between these two locations. 
In the second part of the study, we tried to understand whether these different 
disease phenotypes could be attributed to the different expression and functions 
of the soluble immune checkpoints sCTLA-4, sPD-1 and its ligands.  
An analysis of vascular lesions from temporal artery biopsies of patients with 
GCA showed a reduction in the transcription of the immunoinhibitory ligand 
PD-L1 together with an increased expression of PD-1+ T cells73, suggesting the 
presence of a pro-inflammatory environment. The expression of PD-L1 on 
dendritic cells was particularly low in those patients with higher ESR and CRP73, 
in line with the concept that defective immunoregulatory mechanisms in GCA 
lead to vascular inflammation. This is not the only evidence of the involvement 
of immune checkpoints in the pathogenesis of GCA. In a cross-sectional study 
of 30 patients with GCA, of whom 15 were already receiving glucocorticoid 
treatment, circulating PD-1+ Th cells were reduced in comparison to healthy 
controls107. Circulating T-helper cells expressing the negative checkpoint V-
domain Immunoglobulin-containing suppressor of T cell activation (VISTA) 
were also reduced in number107. On the other hand, arteritic lesions from 
diagnostic temporal artery biopsies showed an increase in VISTA-expressing 
cells and in PD-L1-expressing cells107.  
The relationship between immune checkpoints and inflammatory rheumatic 
disease has gained increased interest in recent years. The introduction of immune 
checkpoint inhibitors (ICIs) has highlighted the close relationship between 
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autoimmunity and immunity against cancer. On the one hand, ICIs have proved 
to be efficacious in several types of cancer56,108–110. On the other hand, ICIs are 
associated with a multitude of immune-mediated adverse effects, including 
endocrine, gastroenterological, renal, cutaneous and articular manifestations111. 
Checkpoints represent a sort of “brake” on the immune system, whose activity 
would be otherwise uncontrolled and would lead to self-damage. Murine models 
with CTLA-4 deficiency die after a few days due to a massive tissue infiltration 
and destruction by lymphocytes112,113. ICIs such as ipilimumab, pembrolizumab, 
atezolizumab and nivolumab block these inhibitory pathways and therefore 
enhance the immune response against tumour cells. This anti-tumour beneficial 
effect, however, comes at a price, represented by immune-related adverse events. 
New-onset inflammatory arthritis appears in about 5-7% of patients with 
malignancy treated with ICIs114. Other possible manifestations include myositis, 
sicca syndrome and sarcoidosis114. A retrospective pharmacovigilance study 
showed an increased risk of myocarditis, pericarditis and vasculitis in patients 
receiving ICIs115. In that series, sixteen cases of PMR were described, as well as 
18 cases of temporal arteritis, of whom five presented with visual impairment115. 
Patients with temporal arteritis were more likely to be treated with anti-CTLA-
4 therapy than with anti-PD-1 or anti-PD-L1 therapy.  
One might wonder whether ICI-induced rheumatic diseases represent a valid 
model to study the “idiopathic” counterparts. In a cohort of patients with ICI-
induced PMR and cases from a literature review72, a considerable portion 
presented with atypical features: peripheral synovitis (including unusual sites 
such as the elbow), positivity of autoantibodies and sicca syndrome. 
Interestingly, two of these patients showed a refractory course and were treated 
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successfully with tocilizumab72. There are other anecdotal reports on the positive 
effect of tocilizumab in cases of ICI-induced arthritis116. This might indicate that 
either IL-6 is involved in the pathogenesis of immune-related adverse events or 
that, once the autoimmunity is triggered, each disease follows its own pathway 
and IL-6 has a pivotal role in rheumatoid arthritis, PMR, and GCA117. In a cohort 
of 14 patients with ICI-induced PMR118, peripheral arthritis was present in 57%, 
compared to 28% of the control group composed of 43 “classical” PMR patients. 
In our study, 25% of patients presented with peripheral arthritis, but its presence 
was not correlated with the concentrations of soluble immune checkpoints. 
The study of ICI-induced rheumatic disease is in its infancy. The available 
evidence might suggest that ICIs can open the Pandora’s box of autoimmunity, 
but they are not responsible for what comes out from that box. Several 
mechanisms have been postulated to explain the pathophysiology of immune-
related adverse events, including a pre-existing and latent autoimmunity119. 
Another point to emphasize considering the ICIs story is that PMR, considered 
by some authors an autoinflammatory disease rather than an autoimmune one120, 
may ultimately be triggered by autoimmune mechanisms. 
The relationship between the soluble and membrane-bound form of immune 
checkpoints is still not fully understood121. Soluble CTLA-4 is almost 
undetectable in healthy subjects68. Levels of sCTLA-4 are increased in patients 
with systemic lupus erythematosus122 and systemic sclerosis123. In patients with 
rheumatoid arthritis and spondyloarthropathies, sCTLA-4 was also increased in 
comparison to controls and, in addition, correlated with disease activity124,125. In 
a recently published report on a cohort of 104 patients with systemic lupus 
erythematosus, levels of sCTLA-4 correlated closely with those of interferon-
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 a126. There are several lines of evidence in support of an immunoregulatory 
effect of sCTLA-4, starting from its first description in 2000127. In human PBMC 
cultures, an experimental antibody blocking only sCTLA-4 (but not the 
membrane-bound form) increased cytokines production128. As a confirmation, 
mice infused with melanoma cells and treated with either an antibody specific to 
sCTLA-4 or a pan-specific anti-CTLA-4 antibody showed a reduction in the 
number of the metastatic sites of 44% and 50%, respectively128. Silencing of 
sCTLA-4 mRNA with RNA interference impaired the function of regulatory T 
cells; the same authors also demonstrated in a murine model that a reduction in 
sCTLA-4 expression was associated with increased susceptibility of developing 
type 1 diabetes129.  
There is still debate on the function of sPD-1: it may block the interactions 
between PD-L1 and CD80, PD-L1 and PD-1, as well as PDL2 and PD-1, thus 
exerting immunostimulatory and anti-tumour effects121. Patients with 
rheumatoid arthritis patients showed high levels of sPD-1 in both sera and 
synovial fluid130, which correlated with disease activity and were reduced by 
methotrexate treatment. In mice with collagen-induced arthritis, the 
administration of sPD-1 enhanced Th1/Th17 response and increased the severity 
of the arthritis130. Patients with systemic sclerosis showed increased levels of 
sPD-1 and sPD-L2, which correlated with different parameters of disease 
severity131. Nevertheless, an inhibitory effect of s-PD1 on T cell activation has 
also been proposed, possibly through reverse signalling involving dendritic 
cells132. 
Zoledronate is a nitrogen-containing bisphosphonate which is indicated for the 
treatment of osteoporosis and bone metastasis. In oncology, zoledronate use is 
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based on the inhibition of bone resorption by osteoclasts, but it may exert an 
anti-tumour effect through other mechanisms 133. In vitro, zoledronate inhibited 
regulatory T cells with a consequent downregulation of immunoinhibitory 
molecules, including CTLA-4134. This sort of immunostimulatory effect of 
zoledronate in cancer might be conceptually linked to immunostimulatory action 
of ICIs. A synergistic action of zoledronate and PD-1 blockade has been 
suggested in a murine model of breast cancer135. We have previously shown that 
zoledronate infusion significantly reduces circulating levels of sCTLA-4 in 
patients with inflammatory rheumatic diseases (Giusti et al, under revision), 
suggesting a sort of “pro-inflammatory” transient state, which might be mediated 
by the reduction of sCTLA-4. 
Our patients with PMR and GCA showed significantly higher levels of sCTLA-
4, sPD-1, sPD-L1 and sPD-L2 in comparison with controls. This finding is in 
line with the existing literature in several other autoimmune 
diseases68,122,123,125,131. Given the several reports of onset of PMR and GCA after 
treatment with ICIs72,136, we sought to analyse soluble immune checkpoints and 
their relationship with different clinical, laboratory and imaging characteristics. 
We did not find significant correlations between the levels of sCTLA-4, sPD-1, 
sPD-L1 and sPD-L2 and disease duration, morning stiffness, CRP, ESR and the 
total burden of vascular and articular inflammation as assessed by FDG-
PET/CT. We also tested whether patients with GCA were characterized by 
differences in circulating immune checkpoints. However, no differences were 
detected in comparison with patients with isolated PMR, either in terms of 
clinical presentation (e.g. presence or absence of headache, jaw claudication, 
systemic inflammation) or imaging-detected vasculitis.  
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There are data suggesting a preferential involvement of one pathway in the 
development of ICI-induced GCA since patients with temporal arteritis were 
more likely to have received anti-CTLA-4 treatment in the aforementioned 
pharmacovigilance study115. On the contrary, the study from Zhang et al.73 
pointed to a significant role of the PD-1 pathway. A trial of abatacept, a CTLA-
4-Ig used for the treatment of rheumatoid arthritis, in patients with GCA showed 
a barely significant difference in relapse-free survival at 12 months in patients 
receiving GC+abatacept compared to those receiving GC only137. Although the 
overall results of this trial were positive, the magnitude of the effect of abatacept 
may suggest that this pathway is not the pivotal one to be targeted for the 
treatment of GCA. An industry-sponsored trial on the use of subcutaneous 
abatacept in patients with GCA (NCT03192969) has been withdrawn. A trial on 
the use of abatacept monotherapy in patients with early-onset PMR, without 
associated glucocorticoids for the first 12 weeks of treatment, is currently 
recruiting (NCT03632187). 
Our results confirm that immune checkpoints are involved in PMR and GCA, as 
highlighted by the increase of their soluble forms in this cohort. However, the 
CTLA-4 and PD-1 pathways do not seem to be the key players in the PMR/GCA 
complex, as suggested by the lack of correlations with the principle articular and 
vascular manifestations in our patients, as well as the limited evidence for the 
efficacy of abatacept in GCA. The increase in soluble immune checkpoint may 
represent a generic marker of hyperactivation of the immune system, as observed 
in many other rheumatic inflammatory diseases122,124,125. Another possible 
interpretation is that the increase of sCTLA-4 in rheumatic diseases may be an 
attempt to dampening the uncontrolled inflammation. 
 55 
The strengths of the study presented in this thesis include the prospective 
inclusion of consecutive, unselected patients; the precise clinical, laboratory and 
imaging assessment of all the patients, and the relatively low number of patients 
already taking glucocorticoids at the time of the tests and evaluations done for 
the study. To the best of our knowledge, this is the largest study analysing 
immune checkpoint molecular expression in patients with PMR and GCA.  
Limitations of this study include the presence of PMR features in almost all 
patients with C-GCA. The ability to focusing on patients with “pure” cranial-
GCA might have allowed the identification of some unique or differentiating 
characteristics of “articular” vs “vascular” disease in these patients. Only a small 
number of patients presented with FUO as the unique manifestation and we had 
no patients with clinical presentations related exclusively to LVV (such as limb 
claudication). Another limitation is represented by the analysis of the soluble 
forms of the immune checkpoints exclusively, without studying the membrane-
bound counterparts. However, our previous study on the effects of zoledronate 
on sCTLA-4 showed that the soluble form may be a good “proxy” for the activity 






PMR and GCA, in both its phenotypes related to cranial and large vessel 
involvement, are diseases with overlapping features of as yet unclear aetiology. 
Results from this study provide additional evidence that these phenotypes 
probably represent multiple facets of a syndrome rather than different 
conditions. FDG-PET/CT is a valuable technique, which offers panoramic view 
of different sites, allowing the detection of both joint and vascular inflammation, 
but also of possible neoplastic and infectious diseases. For this reason, it is a 
valuable tool in the evaluation of patients with FUO. Immune checkpoints are 
dysregulated in both patients with PMR and GCA, but they cannot be used to 
differentiate patients with or without LVV. 
 
Prospective studies on the outcomes of patients with PMR and GCA with 
concomitant LVV are needed to establish the clinical and prognostic impact of 
inflammation of large vessels, in order to ensure the best therapy for these 
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8.1. Classification criteria used in the study. 
Since no formal classification criteria exist for patients with LVV, patients 
fulfilling the 1990 ACR criteria for GCA were defined as having C-GCA in 
absence of obvious clinical signs of peripheral vasculitis (such as arm 
claudication). 
Bird criteria for polymyalgia rheumatica76. 
1. Bilateral shoulder pain and/or stiffness 
2. Onset of illness within 2 weeks 
3. Initial ESR ³40 mm/hour 
4. Morning stiffness >1 hour 
5. Age >65 years  
6. Depression and/or loss of weight 
7. Bilateral upper arm tenderness 
Three or more criteria should be fulfilled. 
1990 criteria for the classification of giant cell arteritis77 
1. Age at disease onset ³50 years: development of symptoms or findings 
beginning at age 50 or older 
2. New headache: new onset of or new type of localized pain in the head 
3. Temporal artery abnormality: temporal artery tenderness to palpation 
or decreased pulsation, unrelated to arteriosclerosis of cervical arteries 
4. Elevated erythrocyte sedimentation rate: erythrocyte sedimentation 
rate ³50 mm/hour by the Westergren method 
5. Abnormal artery biopsy: biopsy specimen with artery showing 
vasculitis characterized by a predominance of mononuclear cell 
infiltration or granulomatous inflammation, usually with 
multinucleated giant cells. 
Three or more criteria should be fulfilled. 
Durack and Street classification of fever of unknown origin48. 
Classic 
1. Temperature >38.3°C 
2. Duration of >3 weeks 
3. Evaluation of at least 3 outpatient visits or 3 days in hospital 
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Nosocomial 
1. Temperature >38.3°C 
2. Patient hospitalized ≥24 hours but no fever or incubating on admission 
3. Evaluation of at least 3 days 
Immune deficient (neutropenic) 
1. Temperature >38.3°C 
2. Neutrophil count ≤ 500 per mm3 
3. Evaluation of at least 3 days 
HIV-associated 
1. Temperature >38.3°C 
2. Duration of >4 weeks for outpatients, >3 days for inpatients 
3. HIV infection confirmed 
 
 72 
8.2. Supplementary table 1 
 




















9.4 (2.2-707.5)  9.9 (2.2-707.5) 6.8 (3-69.5) 16.3 (3.5-47.2) 4 (2.2-15) 0.21 9.1 (2.2-707.5) 10 (2.6-134) 0.23 7 (2.2-707.5) 10 (2.5-180.7) 0.21 
PET vasc2+: PET scan showing at least one vascular region with a visual uptake ³2. PET vasc3+: PET scan showing at least one vascular region 
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